# Wells Fargo & Company

Type: Company (WFC)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/wells-fargo-company
Canonical HTML page: https://gethealthbrief.com/entity/wells-fargo-company

## Recent coverage (2 stories)

### ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand
2026-07-10 14:15:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Full story: https://gethealthbrief.com/story/resmed-analyst-target-sleep-apnea-demand

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:11:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a significant rating upgrade to "Strong-Buy" from Wells Fargo, signaling robust institutional confidence in the peripheral nerve repair specialist. This move, coupled with price target hikes from Jefferies and positive outlooks from Citigroup, underscores a bullish sentiment for the company's clinical and commercial trajectory.
Full story: https://gethealthbrief.com/story/axogen-wells-fargo-strong-buy-upgrade

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.